Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients

Inclusion Criteria: Patients will be screened for eligibility during routine follow-up 4 - 8 weeks after heart transplantation. All of the following conditions must apply prior to administering the investigational medicinal product: * Heart transplant recipient within the last 4 - 8 weeks. * Age between 18 and 70 years. * Informed consent obtained and documented according to Good Clinical Practice (GCP), and national/regional regulations. * No contraindications to coronary angiography with intravascular ultrasound * Estimated glomerular filtration rate \> 20 ml/min/1.73 m2 as assessed by the MDRD formula. Exclusion Criteria: Patients will be excluded from the study if they meet any of the following criteria: * Decompensated liver disease (Child-Pugh class C) * Severe renal failure, i.e. eGFR \< 20 ml/min/1.73 m2 or on renal replacement therapy * Ongoing rejections or infections * Known sensitivity or intolerance to evolocumab or any of the excipients of Repatha® * Prior use of PCSK9 inhibition treatment * Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake * Participation in another clinical trial involving an investigational drug and/or follow-up within 30 days prior to enrolment. * Pregnancy. * Female subject who has either (1) not used at least one highly effective method of birth control for at least 1 month prior to …